Form 4 Lyell Immunopharma Inc For: 27 July
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Lyell Immunopharma Inc (LYEL)
Track today's live Lyell Immunopharma (LYEL) share price, performance and key data on this page with our current NASDAQ:LYEL stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Lyell Immunopharma share price on the NASDAQ exchange. Use the dropdown to switch exchange for the LYEL share price, head to our technical summary section, which provides analysis on Lyell Immunopharma share price buy/sell indicators using real-time data (or discuss the Lyell Immunopharma (LYEL) stock price today with other investors in the Lyell Immunopharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:LYEL share price (ISIN: US55083R2031) to enhance your trading decisions with our free investment tools and resources.
What Is the Lyell Immunopharma Inc Share Price Today?
The Lyell Immunopharma share price today is 13.250.
What Is the Stock Symbol for Lyell Immunopharma Inc
The stock symbol (or 'ticker') for Lyell Immunopharma Inc is "LYEL."
What Stock Exchange Does Lyell Immunopharma Inc Trade On?
Lyell Immunopharma Inc is listed and trades on the NASDAQ stock exchange.
Is Lyell Immunopharma Inc a Good Stock to Buy?
Determining whether Lyell Immunopharma (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:LYEL share price (ISIN: US55083R2031) to enhance your trading decisions with our free investment tools and resources.
What Is the Lyell Immunopharma Inc Share Price Today?
The Lyell Immunopharma share price today is 13.250.
What Is the Stock Symbol for Lyell Immunopharma Inc
The stock symbol (or 'ticker') for Lyell Immunopharma Inc is "LYEL."
What Stock Exchange Does Lyell Immunopharma Inc Trade On?
Lyell Immunopharma Inc is listed and trades on the NASDAQ stock exchange.
Is Lyell Immunopharma Inc a Good Stock to Buy?
Determining whether Lyell Immunopharma (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
NASDAQ
Currency in USD
13.250
+0.260(+2.00%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.900
13.490
52 wk Range
9.280
45.000
Earnings results expected in 14 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
12.90013.490
52 wk Range
9.28045.000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LYEL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
38.143
Upside
+187.87%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Form 4 Lyell Immunopharma Inc For: 17 July- Investing.com
- Form 4 Lyell Immunopharma Inc For: 27 July
- Investing.com
Form 4 Lyell Immunopharma Inc For: 21 July- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
6 Buy
0 Hold
1 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 38.143
(+187.87% Upside)
Earnings
Latest Release
06/05/2026
EPS / Forecast
-1.10 / -0.18
Revenue / Forecast
2K / --
Compare LYEL to Peers and Sector
Metrics to compare | LYEL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLYELPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.3x | −5.3x | −0.3x | |
PEG Ratio | −0.03 | 0.06 | 0.00 | |
Price/Book | 1.2x | 2.9x | 2.6x | |
Price / LTM Sales | 10,220.7x | 7.3x | 3.0x | |
Upside (Analyst Target) | 238.7% | 453.5% | 56.3% | |
Fair Value Upside | Unlock | 17.9% | 9.8% | Unlock |
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Lyell Immunopharma (NASDAQ: LYEL) Share Price Today?
The Lyell Immunopharma stock price today is 13.250 USD.
What Stock Exchange Does Lyell Immunopharma (LYEL) Trade On?
Lyell Immunopharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Lyell Immunopharma?
The stock symbol (also called a 'ticker') for Lyell Immunopharma is "LYEL."
What Is the Current Lyell Immunopharma Market Capitalisation?
As of today, Lyell Immunopharma (NASDAQ: LYEL) market cap is 323.460M USD.
What Is Lyell Immunopharma's (LYEL) Earnings Per Share (TTM)?
The Lyell Immunopharma EPS is currently -13.056 (Trailing Twelve Months).
When Is the Next Lyell Immunopharma Earnings Date?
Lyell Immunopharma's next earnings report will be released on 12/08/2026.
Is LYEL a Buy or Sell From a Technical Analyst Perspective?
Based on today's Lyell Immunopharma moving averages and other technical indicators, the daily buy/sell signal for LYEL stock is Strong Sell.
How Many Times Has Lyell Immunopharma Stock Split?
Lyell Immunopharma has split 1 times. (See the LYEL stock split history page for full effective split date and price information.)
How Many Employees Does Lyell Immunopharma Have?
Lyell Immunopharma has 161 employees, based on their latest Companies House report.
What is the current trading status of Lyell Immunopharma (NASDAQ: LYEL)?
As of 29/07/2026, Lyell Immunopharma (LYEL) is trading at a share price of 13.250 USD, with a previous close of 12.990 USD. The stock has fluctuated within a day range of 12.900 USD to 13.490 USD, while its 52-week range spans from 9.280 USD to 45.000 USD.
What Is Lyell Immunopharma (LYEL) Price Target According to Analysts?
The average 12-month price target for Lyell Immunopharma is 38.143 USD, with a high estimate of 49 USD and a low estimate of 12 USD. 6 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +187.87% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.